Replimune CEO granted new options and RSUs

Replimune Group, Inc. disclosed that Chief Executive Officer Sushil Patel received new equity awards as part of his compensation.

Rhea-AI Filing Summary

Replimune Group, Inc. disclosed that Chief Executive Officer Sushil Patel received new equity awards as part of his compensation. He was granted an employee stock option for 376,860 shares of common stock at an exercise price of $7.61 per share, expiring on April 1, 2036. According to the vesting schedule, 25% of the option vests on April 1, 2027, with the remainder vesting in 36 approximately equal monthly installments. Patel also received 251,240 restricted stock units (RSUs), each representing one share of common stock. The RSUs vest 25% on May 15, 2027, with the balance vesting in three approximately equal annual installments through May 15, 2030, contingent on continued service. Following these awards, he directly owns 784,816 shares of common stock. These are compensation-related grants rather than open-market purchases.

Insider Trade Summary

Grant/Award: 628,100 shares

Grant/Award 2 txns

Insider Patel Sushil

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (right to buy)	376,860	$0.00	$0.00
Grant/Award	Common Stock	251,240	$0.00	$0.00

Holdings After Transaction: Employee Stock Option (right to buy) — 376,860 contracts (Direct); Common Stock — 784,816 shares (Direct)

Footnotes (2)

1. F1. Represents shares of the Issuer's common stock issuable upon settlement of restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. 25% of the RSUs will vest on May 15, 2027 and the remainder will vest in three approximately equal annual installments thereafter until May 15, 2030, subject to the Reporting Person's continuous service to the Issuer.
2. F2. 25% of the shares underlying this stock option vest on April 1, 2027, and the remainder of the shares underlying this stock option vest in 36 approximately equal monthly installments thereafter.

Key Figures

Stock options granted: 376,860 options Option exercise price: $7.61 per share Option expiration: April 1, 2036 +3 more

6 metrics

Stock options granted 376,860 options Employee stock option grant on April 1, 2026

Option exercise price $7.61 per share Exercise price for 376,860 options

Option expiration April 1, 2036 Expiration date of granted options

RSUs granted 251,240 RSUs Restricted stock units granted on April 1, 2026

RSU initial vesting 25% on May 15, 2027 First vesting date for RSU grant

Common shares after grant 784,816 shares Direct common stock holdings after April 1, 2026 awards

Key Terms

Employee Stock Option, restricted stock units ("RSUs"), vesting, contingent right to receive, +1 more

5 terms

Employee Stock Option financial

"Represents an Employee Stock Option (right to buy) with an exercise price of $7.61"

An employee stock option is a promise that lets a worker buy company shares later at a predetermined price, often after they stay for a certain period or meet performance goals — think of it like a coupon that locks in today's price for a future purchase. It matters to investors because options align employees’ incentives with company performance, can increase the number of shares outstanding (dilution) when exercised, and represent a compensation cost that affects reported profits and shareholder value.

restricted stock units ("RSUs") financial

"Represents shares issuable upon settlement of restricted stock units ("RSUs") granted to the Reporting Person"

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

vesting financial

"25% of the RSUs will vest on May 15, 2027 and the remainder will vest in three approximately equal annual installments"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

contingent right to receive financial

"Each RSU represents a contingent right to receive one share of the Issuer's common stock"

exercise price financial

"25% of the shares underlying this stock option vest on April 1, 2027, with an exercise price of $7.61"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did Replimune (REPL) CEO Sushil Patel receive?

Sushil Patel received an option to buy 376,860 Replimune shares at $7.61 and 251,240 RSUs. Both awards vest over several years, tying much of his compensation to the company’s long-term stock performance and his continued service.

Are Sushil Patel’s new Replimune (REPL) awards open-market share purchases?

No, the Form 4 shows compensation grants, not open-market purchases. The 376,860 options and 251,240 RSUs were awarded by the company at no purchase price, with vesting schedules extending from 2027 through 2030, subject to continued employment.

What is the vesting schedule for Sushil Patel’s new Replimune (REPL) stock options?

The stock options vest 25% on April 1, 2027, with the remaining shares vesting in 36 approximately equal monthly installments. This structure encourages long-term alignment, as full vesting occurs gradually after the initial three-year cliff date.

How do Sushil Patel’s Replimune (REPL) RSUs vest over time?

The 251,240 RSUs vest 25% on May 15, 2027, then in three approximately equal annual installments through May 15, 2030. Each RSU converts into one Replimune common share when vested, conditioned on Patel’s continuous service with the company.

How many Replimune (REPL) shares does Sushil Patel hold after these grants?

After the April 1, 2026 grants, Sushil Patel directly owns 784,816 shares of Replimune common stock. This total reflects his post-transaction holdings as reported, providing a snapshot of his direct equity stake following the new awards.

What is the exercise price and expiration date of the new Replimune (REPL) stock options?

The new employee stock options have an exercise price of $7.61 per share and expire on April 1, 2036. Patel can only benefit if Replimune’s market price exceeds this level after vesting and before the options expire.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/07/2026 - 09:09 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Patel Sushil

(Last) (First) (Middle)

C/O REPLIMUNE GROUP, INC.

500 UNICORN PARK DRIVE, SUITE 303

(Street)

WOBURN MASSACHUSETTS 01801

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Replimune Group, Inc. [ REPL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/01/2026		A		251,240(1)	A	$0	784,816	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$7.61	04/01/2026		A		376,860		(2)	04/01/2036	Common Stock	376,860	$0	376,860	D

Explanation of Responses:

1. Represents shares of the Issuer's common stock issuable upon settlement of restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. 25% of the RSUs will vest on May 15, 2027 and the remainder will vest in three approximately equal annual installments thereafter until May 15, 2030, subject to the Reporting Person's continuous service to the Issuer.

2. 25% of the shares underlying this stock option vest on April 1, 2027, and the remainder of the shares underlying this stock option vest in 36 approximately equal monthly installments thereafter.

Remarks:

This Form 4 is being filed late due to inadvertent administrative error.

	/s/ Shawn Glidden, attorney-in-fact	04/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)